Rezolute Reports $77.6 Million Net Loss for Fiscal Year Ending June 30, 2026

Rezolute, Inc. reported a net loss of $77.6 million for the fiscal year ending June 30, 2026, compared to a net loss of $74.4 million in the previous year. The company's total operating expenses increased to $82.97 million, up from $79.89 million in 2025, primarily driven by a significant rise in general and administrative expenses, which surged by 59% to $29.17 million. In contrast, research and development expenses decreased by 13% to $53.80 million, reflecting reduced costs associated with the clinical development of its lead asset, ersodetug.

The company did not generate any revenue during the fiscal year, continuing its trend as a clinical-stage biopharmaceutical firm focused on developing therapies for hyperinsulinism. As of June 30, 2026, Rezolute had cash and cash equivalents of $10.6 million and investments in marketable debt securities totaling $97.2 million, providing a total capital resource of $107.8 million. This is expected to sustain operations for at least the next 12 months, although the company anticipates needing additional capital to fund ongoing clinical trials and other activities.

In terms of strategic developments, Rezolute's Phase 3 clinical trial, known as the sunRIZE study, for ersodetug in congenital hyperinsulinism did not meet its primary or key secondary endpoints. However, the company reported statistically significant reductions in hypoglycemia events in secondary analyses. Following discussions with the FDA, Rezolute is preparing to submit comprehensive datasets for independent evaluation, which may influence the regulatory path forward for ersodetug. The company is also actively enrolling participants in its upLIFT Phase 3 study for tumor-related hypoglycemia, with topline results expected by the end of 2026.

Operationally, Rezolute's workforce was reduced by 29 employees in December 2025 to streamline operations and preserve capital. As of June 30, 2026, the company employed 58 full-time staff, with 40 dedicated to research and development. The company has received inquiries from physicians regarding the use of ersodetug in expanded access programs, indicating interest in its potential applications. The total addressable market for congenital hyperinsulinism in the U.S. is estimated at over 1,500 individuals, while the market for tumor-related hypoglycemia is projected at approximately 3,000 patients annually.

Looking ahead, Rezolute aims to align with the FDA on the next steps for ersodetug in congenital hyperinsulinism and to complete enrollment in the upLIFT study. The company plans to submit a Biologics License Application for ersodetug in mid-2027, contingent on supportive clinical data. Despite the challenges faced in clinical trials, Rezolute remains focused on advancing its pipeline and addressing the significant unmet medical needs associated with hyperinsulinism.